TaiGen Expects First Cross-Strait Drug Approval In China Next Year
This article was originally published in PharmAsia News
Executive Summary
TaiGen Biotechnology said it anticipates the first China approval of a Taiwan drug under a pharmaceutical cooperation agreement between the two countries.